Results 241 to 250 of about 113,281 (294)
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.Tendon injuries in diabetes heal poorly, with unclear drivers of extracellular matrix disruption and altered mechanics. This narrative review synthesizes in vitro, animal, and human studies, highlighting serum advanced glycation end products as potential systemic contributors.
Eric J. Gutierrez +3 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies
Expert Opinion on Drug Safety, 2018Type 2 diabetes (T2D), a multifactorial and chronic disease, requires in an elevated percentage of patients the association of several antidiabetic drugs to achieve optimal glycemic control. Dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium-glucose cotransporter inhibitors (SGLT2i) are new classes of oral antidiabetic drugs developed over the last ...
Maria Molina-Vega +2 more
exaly +3 more sources
Diabetes, Obesity and Metabolism, 2018 To assess the efficacy and safety of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors plus a dipeptidyl peptidase‐4 (DPP‐4) inhibitor in patients with type 2 diabetes mellitus (T2DM), we performed a systematic review and meta‐analysis of 14 randomized ...
Dandan Li +2 more
exaly +2 more sources
Pharmacoeconomic analysis of DPP-4 inhibitors
Die Pharmazie, 2013Dipeptidyl peptidase-4 (DPP-4) inhibitors and other incretin-related drugs have attracted attention as antidiabetic agents, but they are expensive. The Japanese government has adopted a policy of reducing healthcare costs, and medical institutions must provide medical care while considering economic efficiency.
H, Teramachi +6 more
openaire +3 more sources
The Research Progress of DPP-4 Inhibitors
Mini-Reviews in Medicinal Chemistry, 2020Diabetes mellitus (DM) is a metabolic disease, and diabetes patients have long-term higher blood sugar levels than standard. Most people with diabetes have complications that greatly affect their standard of living. Patients with type 2 DM occupy the vast majority of all diabetes patients.
Zhi-Gang, Sun +2 more
openaire +2 more sources
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013 Miyako KishimotoDepartment of Diabetes and Metabolic Medicine, Center Hospital, Tokyo, Japan; Diabetes and Metabolism Information Center, Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, JapanAbstract: Dipeptidyl peptidase-
Kishimoto M
exaly +1 more source
Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
Current Drug Safety, 2021Abstract:: Dipeptidyl peptidase-4 (DPP-4) inhibitors or gliptins belong to the class of incretin mimetics. These drugs have been available on the market for the management of type 2 diabetes mellitus (T2DM) for over a decade. Sitagliptin, linagliptin, vildagliptin, saxagliptin and alogliptin are widely available globally, whilst anagliptin ...
Nikhila A. Subrahmanyan +3 more
openaire +2 more sources
DPP-4 inhibitors: focus on safety
Expert Opinion on Drug Safety, 2014Dipeptidyl peptidase inhibitors (DPP-4-i) are highly selective inhibitors of the enzyme DPP-4. They act by increasing levels of incretin hormones, which have potent effects on insulin and glucagon release, gastric emptying, and satiety. Our goal is to review the safety issues related to DPP-4-i.This review is based upon a PubMed search of the ...
Sri Harsha, Tella, Marc S, Rendell
openaire +2 more sources
DPP-4 Inhibitors in Clinical Practice
Postgraduate Medicine, 2009Type 2 diabetes is a very common worldwide disorder, with major consequences for patients, society, and health care services. Good glycemic control is an important aspect of diabetes management because it has a significant impact on diabetes-related microvascular and possibly macrovascular complications.
Palalau, Anna I. +3 more
openaire +3 more sources
DPP-4 inhibitors and atherosclerosis: The promise
Atherosclerosis, 20130021-9150/$ e see front matter 2013 Elsevier Irela http://dx.doi.org/10.1016/j.atherosclerosis.2012.12.033 The major cause of mortality and morbidity in diabetes is cardiovascular disease (CVD). Novel therapies that have now been introduced for the treatment of diabetes includingmodulation of the Incretin axis with either glucagon like peptide-1 ...
Ishwarlal, Jialal, Mandeep, Bajaj
openaire +2 more sources